Editorials

199 Effect of Synbiotic Therapy on Gut–Derived Uremic Toxins and the Intestinal Microbiome in Patients with CKD
Nosratola D. Vaziri
See related article on page 223.

202 Structural Predictors of Renal Function Decline
Susanne B. Nicholas
See related article on page 254.

205 The Burden of Harm—What Is the Ideal Vascular Access for Home Hemodialysis?
Emilie Trinh and Christopher T. Chan
See related article on page 298.

Original Articles

Chronic Kidney Disease

207 Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC
Paul Drawz, Sabarish Ayyappan, Mehdi Nouraie, Santosh Saraf, Victor Gordeuk, Thomas Hostetter, Mark T. Gladwin, and Jane Little

216 CKD and Acute and Long-Term Outcome of Patients with Peripheral Artery Disease and Critical Limb Ischemia
Florian Lüders, Holger Bunzemeier, Christiane Engelbertz, Nasser M. Malyar, Matthias Meyborg, Norbert Roeder, Klaus Berger, and Holger Reinecke

223 Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial
Megan Rossi, David W. Johnson, Mark Morrison, Elaine M. Pascoe, Jeff S. Coombes, Josephine M. Forbes, Cheuk-Chun Szeto, Brett C. McWhinney, Jacobus P.J. Ungerer, and Katrina L. Campbell
See related editorial on page 199.

232 Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials
Leena Patel, Lisa M. Bernard, and Grahame J. Elder

Clinical Nephrology

245 Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid–Resistant Nephrotic Syndrome

Diabetes and the Kidney

254 Structural Predictors of Loss of Renal Function in American Indians with Type 2 Diabetes
See related editorial on page 202.
Epidemiology and Outcomes

262  **Association of APOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney Biopsy**

271  **Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension**
Ernesto Paoletti, Luca De Nicola, Francis B. Gabbai, Paolo Chiodini, Maura Ravera, Laura Pieracci, Sonia Marre, Paolo Cassottana, Sergio Lucà, Simone Vettoretti, Silvio Borrelli, Giuseppe Conte, and Roberto Minutolo

280  **Residual Associations of Inflammatory Markers with eGFR after Accounting for Measured GFR in a Community-Based Cohort without CKD**
Jørgen Schei, Vidar T.N. Stefansson, Ulla Dorte Mathisen, Bjørn O. Eriksen, Marit D. Solbu, Trond G. Jenssen, and Toralf Melsom

287  **Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD**
Marta Gracia, Àngels Betriu, Montserrat Martínez-Alonso, David Arroyo, Marià Abajo, Elvira Fernández, and José M. Valdivielso on behalf of the NEFRONA Investigators

ESRD and Chronic Dialysis

298  **Association of Vascular Access Type with Mortality, Hospitalization, and Transfer to In-Center Hemodialysis in Patients Undergoing Home Hemodialysis**
See related editorial on page 205.

Geriatric Nephrology

308  **Bicarbonate Concentration, Acid-Base Status, and Mortality in the Health, Aging, and Body Composition Study**

Renal Transplantation

317  **Epidemiology of Kidney Discard from Expanded Criteria Donors Undergoing Donation after Circulatory Death**
Sunita K. Singh and S. Joseph Kim

324  **Validating Early Post-Transplant Outcomes Reported for Recipients of Deceased Donor Kidney Transplants**
Vishnu S. Potluri, Chirag R. Parikh, Isaac E. Hall, Joseph Ficek, Mona D. Doshi, Isabel Butrymowicz, Francis L. Weng, Bernd Schröppel, Heather Thiessen-Philbrook, and Peter P. Reese

Renal Immunology

332  **Immunosuppressive Medications**
Alexander C. Wiseman

Ethics Series

344  **The Role of Time-Limited Trials in Dialysis Decision Making in Critically Ill Patients**
Jennifer S. Scherer and Jean L. Holley
On the Cover

What’s the diagnosis? A 31-year-old woman with history of systemic lupus erythematos (SLE), ITP, membranous nephropathy, stage 3 CKD, cerebrovascular accident, and deep venous thrombosis presented with acute kidney injury (serum creatinine increased from 1.8 mg/dl to 4.7 mg/dl over 3 weeks). Urinalysis revealed 3+ protein and large blood while urine sediment demonstrated 7-10 dysmorphic red blood cells/HPF and 3-5 white blood cells/HPF. There were no casts present. ANA was 1:160 while complement levels were normal and anti-double-stranded DNA was negative. A kidney biopsy was performed. The left panel of the cover image shows near obliteration of the intrarenal vessel with fragmented red blood cells in the wall with initial thickening and thrombi occluding the lumen. The right panel shows luminal thrombus with intimal hyperplasia/fibrosis. Antibodies to β2-glycoprotein-1 were elevated. The patient was diagnosed with antiphospholipid antibody syndrome (APLS) secondary to SLE. The patient received corticosteroids and underwent plasmapheresis. Rituximab was subsequently initiated. Kidney function improved with serum creatinine plateauing at 2.1 mg/dl. APLS is an autoimmune disorder characterized by recurrent arterial or venous thrombosis and/or pregnancy loss, in the presence of persistently elevated levels of anticardiolipin antibodies (and/or anti-β2-glycoprotein-1 antibodies) and/or evidence of circulating lupus anticoagulant. Kidney involvement is quite common in both primary and secondary APLS. Thrombosis may occur at any location within the renal vasculature, and the size, type and site of the vessel involved drives the renal manifestation in APLS. Included are renal artery stenosis and/or renovascular hypertension, renal infarction, APLS nephropathy, renal vein thrombosis, and increased allograft vascular thrombosis in transplant patients. In addition, renal manifestations of APLS may co-exist with other pathologies, such as proliferative SLE nephritis. The patient described suffered from APLS nephropathy, which is characterized by kidney injury due to vascular lesions in the arterioles and glomeruli. Thrombotic microangiopathy, as seen in this patient, is the most characteristic lesion of APLS nephropathy and is manifested by fibrin thrombi containing fragmented blood cells along with endothelial cell edema, both which narrow or occlude the vascular lumen. Treatment includes anticoagulation, while corticosteroids and immunosuppressive therapy may sometimes be added. This is particularly true in the setting of catastrophic APLS. Plasmapheresis/plasma exchange is frequently performed in this setting. Rituximab have also been utilized in some cases. (Images and text provided by Mark A. Perazella, MD, and Gilbert Moeckel, MD, Yale University School of Medicine, New Haven, Connecticut)